This is exciting vaccine news! Saturday, Oct 29th the FDA approved the Wyeth/Pfizer vaccine Trumenba for the prevention of Neisseria meningitidis serogroup b infection aka: Serogroup b Meningicoccal Disease. This vaccine is the first vaccine to prevent Serogroup b meningicoccal disease and is a welcome addition to our arsenal of disease prevention strategies in the US. The FDA used an accelerated approval pathway due to recent outbreaks on US college campuses. This new vaccine is indicated for patients 10-25yrs and is a 3 dose series. See full prescribing information for more details on the proper use of Trumenba.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm